Cargando…

A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer

BACKGROUND: Although the incidence of lung cancer in elderly individuals has been increasing in recent years, the number of clinical trials designed specifically for elderly patients with advanced non‐small cell lung cancer (NSCLC) is still limited. To fulfill this unmet medical need, we conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yabuki, Yohei, Hanibuchi, Masaki, Takeuchi, Eiji, Haku, Takashi, Kanematsu, Takanori, Nishimura, Naoki, Toyoda, Yuko, Mitsuhashi, Atsushi, Otsuka, Kenji, Sato, Seidai, Goto, Hisatsugu, Yoneda, Hiroto, Ogino, Hirokazu, Nokihara, Hiroshi, Tsutomu, Shinohara, Nishioka, Yasuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643789/ https://www.ncbi.nlm.nih.gov/pubmed/37718463 http://dx.doi.org/10.1111/1759-7714.15115

Ejemplares similares

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Yoneda, Hiroto, et al.
Publicado: (2021)

Efficacy and safety of second‐line chemotherapy for patients with advanced non‐small cell lung cancer complicated by interstitial lung disease
por: Otsuka, Kenji, et al.
Publicado: (2022)

FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma
por: Takahashi, Hiroki, et al.
Publicado: (2023)

S‐1 eliminates MDSCs and enhances the efficacy of PD‐1 blockade via regulation of tumor‐derived Bv8 and S100A8 in thoracic tumor
por: Nguyen, Na T., et al.
Publicado: (2022)

Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
por: Nokihara, Hiroshi, et al.
Publicado: (2022)

Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study
por: Sakurada, Takumi, et al.
Publicado: (2022)

Development, validation, and comparison of gene analysis methods for detecting EGFR mutation from non-small cell lung cancer patients-derived circulating free DNA
por: Hanibuchi, Masaki, et al.
Publicado: (2019)

A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab
por: Sako, Masahiro, et al.
Publicado: (2021)

Radiation therapy induces an abscopal effect and upregulates programmed death‐ligand 1 expression in a patient with non‐small cell lung cancer
por: Morita, Yutaka, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody
por: Ichihara, Seiya, et al.
Publicado: (2022)

Programmed death (PD)‐1/PD‐ligand 1 blockade mediates antiangiogenic effects by tumor‐derived CXCL10/11 as a potential predictive biomarker
por: Mitsuhashi, Atsushi, et al.
Publicado: (2021)

Multidisciplinary treatment of skeletal muscle metastasis from lung cancer: A case of triceps muscle metastasis of lung squamous cell cancer
por: Haji, Keiko, et al.
Publicado: (2021)

Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
por: Laslett, Nicole F., et al.
Publicado: (2018)

The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice
por: Van, Trung The, et al.
Publicado: (2010)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab
por: Mitsuhashi, Atsushi, et al.
Publicado: (2015)

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
por: Schuette, Wolfgang, et al.
Publicado: (2017)

Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer
por: Tobiume, Makoto, et al.
Publicado: (2022)

Better efficacy of intrapleural infusion of bevacizumab with pemetrexed for malignant pleural effusion mediated from nonsquamous non-small cell lung cancer
por: Song, Xinyu, et al.
Publicado: (2018)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
por: Huang, Meijuan, et al.
Publicado: (2021)

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015
por: Kozuki, Toshiyuki, et al.
Publicado: (2016)

An Open‐Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non‐Small Cell Lung Cancer
por: Patil, Pradnya Dinkar, et al.
Publicado: (2019)

Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
por: Shih, Jin-Yuan, et al.
Publicado: (2020)

Single pemetrexed is noninferior to platinum-based pemetrexed doublet as first-line treatment on elderly Chinese patients with advanced nonsquamous nonsmall cell lung cancer
por: Pu, Xiaolin, et al.
Publicado: (2017)

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Development of improved method to identify and analyze lung fibrocytes with flow cytometry in a reporter mouse strain
por: Kawano, Hiroshi, et al.
Publicado: (2020)

Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials
por: Langer, Corey J., et al.
Publicado: (2016)

A New Quinoline Derivative MS‐209 Reverses Multidrug Resistance and Inhibits Multiorgan Metastases by P‐glycoprotein‐expressing Human Small Cell Lung Cancer Cells
por: Nokihara, Hiroshi, et al.
Publicado: (2001)

Radiation-associated Angiosarcoma Presenting as Massive Pleural Effusion
por: Ogino, Hirokazu, et al.
Publicado: (2021)

Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
por: Imai, Hisao, et al.
Publicado: (2023)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target
por: Huang, Jun, et al.
Publicado: (2013)

A case of pulmonary pleomorphic carcinoma with malignant phenotypes induced by ZEB1-associated epithelial-mesenchymal transition
por: Kondo, Mayo, et al.
Publicado: (2018)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non–Small Cell Lung Cancer
por: Brooks, Gabriel A., et al.
Publicado: (2018)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1a656fhqt01qqtsku9pqs18pug